Neuraceq Generic Name & Formulations
Mechanism of Action
Florbetaben F 18 is a F18-labeled stilbene derivative, which binds to ß-amyloid plaques in the brain.
For positron emission tomography (PET) imaging of the brain to estimate ß-amyloid neuritic plaque density in adults with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
Limitations of Use
A positive scan does not establish AD diagnosis or any other cognitive disorder. Safety and efficacy not established for predicting development of dementia or other neurologic conditions; or monitoring response to therapies.
Neuraceq Dosage and Administration
Give as slow IV bolus at a rate of 6secs/mL into large vein in the arm. 300 MBq (8.1mCi), max 30mcg mass dose, in a total volume of up to 10mL. Follow with saline flush of ~10mL. Acquire PET images over 15–20mins starting 45–130mins after inj.
Neuraceq Boxed Warnings
Risk for radiation exposure. Should only be used by trained and experienced physicians in the safe use and handling of radioactive materials to minimize radiation exposure. Risk for image misinterpretation and other errors. Pregnancy. Nursing mothers: pump and discard breast milk for 24hrs post-inj.
Plasma protein bound: 98.5%.
Renal. Half-life: ~1hr.
Neuraceq Adverse Reactions
Inj site reactions (erythema, irritation, pain).
Neuraceq Clinical Trials
Neuraceq Patient Counseling